{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:13:07Z","timestamp":1740978787727,"version":"3.38.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtocrr.2024.100782","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T08:14:19Z","timestamp":1734509659000},"page":"100782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY"],"prefix":"10.1016","volume":"6","author":[{"given":"Jill","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy","family":"Elkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bellinda L.","family":"King-Kallimanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tendai","family":"Chihuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alecia","family":"Clary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teri","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upal","family":"Basu Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2024.100782_bib1","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2024.100782_bib2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2024.100782_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2024.100782_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11523-021-00848-9","article-title":"A\u00a0real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical Characteristics and Outcomes","volume":"16","author":"Chouaid","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtocrr.2024.100782_bib5","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/j.cllc.2021.01.019","article-title":"Access to tyrosine kinase inhibitors and survival in patients with advanced EGFR+ and ALK+ positive non-small-cell lung cancer treated in the real-world","volume":"22","author":"Goulart","year":"2021","journal-title":"Clin Lung Cancer"},{"year":"2023","series-title":"Stata Statistical Software: Release 18","key":"10.1016\/j.jtocrr.2024.100782_bib6"},{"year":"2022","series-title":"The R Project for Statistical Computing","key":"10.1016\/j.jtocrr.2024.100782_bib7"},{"key":"10.1016\/j.jtocrr.2024.100782_bib8","first-page":"362","article-title":"Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma","volume":"16","author":"Zhou","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jtocrr.2024.100782_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2019.07.031","article-title":"The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma","volume":"136","author":"Lee","year":"2019","journal-title":"Lung Cancer"},{"year":"2025","series-title":"Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. Version 7.2025","key":"10.1016\/j.jtocrr.2024.100782_bib10"},{"key":"10.1016\/j.jtocrr.2024.100782_bib11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers12082313","article-title":"Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe","volume":"12","author":"Uyl-de Groot","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2024.100782_bib12","doi-asserted-by":"crossref","first-page":"e1774","DOI":"10.1200\/OP.20.01023","article-title":"Association between Medicare\u2019s national coverage determination and utilization of next-generation sequencing","volume":"17","author":"Sheinson","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtocrr.2024.100782_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/OP.22.00611","article-title":"Compromised outcomes in stage IV non-small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data","volume":"20","author":"Scott","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtocrr.2024.100782_bib14","article-title":"Real-world outcomes of treatment strategy between first-line osimertinib, first\/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC","volume":"5","author":"Uehara","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.jtocrr.2024.100782_bib15","doi-asserted-by":"crossref","first-page":"v914","DOI":"10.1093\/annonc\/mdz394.076","article-title":"LBA5_PR - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","volume":"30","author":"Ramalingam","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2024.100782_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s41687-022-00533-z","article-title":"Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow","volume":"6","author":"Kastrati","year":"2022","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.jtocrr.2024.100782_bib17","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2024.100782_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100782_bib19","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.jtocrr.2024.100782_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0000000000000246","article-title":"Cisplatin or carboplatin for advanced non-small-cell lung cancer?","volume":"9","author":"Sun","year":"2014","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:05:05Z","timestamp":1740888305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364324001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666364324001528"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100782","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100782"}}